-
Most Popular
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Healthcare Stocks: Peering Into an Amazing — and Profitable — Future
From AI to genomics to robots, the number of possible new discoveries in the next 10+ years is endless. Invest in healthcare stocks while it’s still early enough to make life-changing returns.
6 Giant Investing Trends for 2020 That You Don’t Want to Miss
These investing trends for 2020 cover trends that will disrupt everything from the housing market to the cars we drive. Don't miss out.
Ignore the Canopy Growth Ambulance Chasers
On Nov. 21, Canopy Growth responded to the potential class-action suits. CGC stock fell on the news. Should shareholders be concerned?
Aphria Stock May Be Headed Higher, But It’s Too Soon to Tell
Canadian cannabis producer Aphria hit an all-time low of $3.76 Nov. 19. Since then, Aphria stock has recovered nicely. Is that the bottom?
Should Investors Buy or Sell Canopy Stock Going Into 2020?
Investors dumped CGC stock following its most recent earnings report. But Canopy Growth stock is starting to bounce back now.
Canopy Growth Stock Sparks Plenty of Dead-Cat Debate After a Recent Rally
Cannabis stocks are going through some drama, but when the smoke clears, Canopy Growth stock could be seen as a winner.
5 Things Aurora Cannabis Must Do to Get ACB Stock Back on Track
Things have gone from bad to worse for ACB stock investors in the past month. Management needs to get serious about making some aggressive changes to get Aurora stock back on track.
The More You Look, the Less Compelling Aurora Stock Seems
Cash burn will result in further equity dilution. Medicinal cannabis growth is likely to be slow with little evidence-backed research.
Cronos Stock Gets Closer to Being a Buy, but It’s Not There Yet
Cronos stock long has been the pot stock for investors who don't like pot stocks. That might be enough for a buy at some point.
Aurora Cannabis Stock Faces a Cold Winter, Rapid Cash Burn
Cash is now king in the marijuana market, and Aurora Cannabis is among those cutting back. Aurora stock depends on U.S. legalization.
Near-Term Pain Will Bring Aurora Cannabis Stock Long-Term Gains
The market is having trouble seeing the forest through the trees on ACB stock. So long as this remains true, shares won't rebound.
The Most Overlooked Investment Theme Heading Into 2020
Chinese biotech stocks are set for not just 10X growth … not 20X growth … not even 50X growth … but at least 100X growth.
Cannabis Stocks: The Latest Bump Is Only the Beginning
If you are bold enough to act now, there is potential for life-changing profits in cannabis stocks.
Investors Should Stop Calling Tilray Stock a Top-Tier Marijuana Name
Hope for U.S. legalization helped Tilray stock, but financial conditions indicate it may struggle to remain top-tier or perhaps, survive.
The Long-Term Cannabis Story Makes Aurora Stock a Strong Buy
With the MORE Act, higher U.S. approval and presidential candidates commenting, there’s plenty of growth for Aurora stock.
Amarin Stock’s Big Q4 Gains May Not Last as Big Dogs are Barking
Thanks to the effective cardiovascular drug Vascepa, Amarin stock has enjoyed an outsized performance so far this year. However, over the horizon stands big pharmaceutical competitors that are ready to spoil the party.
Consider Adding New Positions in U.S. Cannabis Stocks
It's no secret Matt McCall is searching for emerging trends. This week, he discusses cannabis stocks and a breakthrough biotech therapy.
3 Reasons Why the Bottom Could Be in for Canopy Growth Stock
But with marijuana stocks spilling so much red ink in the green market, does CGC stock provide an opportunity for contrarians?
